Pembrolizumab Shows Promise in Non-Small Cell Lung Cancer

Share this content:
PD-1 inhibition with pembrolizumab is showing early promise for some patients with advanced non-small-cell lung cancer.
PD-1 inhibition with pembrolizumab is showing early promise for some patients with advanced non-small-cell lung cancer.

Programmed cell death 1 (PD-1) inhibition with pembrolizumab is showing early promise for some patients with advanced non-small-cell lung cancer, according to preliminary findings published in the New England Journal of Medicine.

The research was published to coincide with the annual meeting of the American Association for Cancer Research, held in Philadelphia.

The study involved 495 patients in the advanced stages of non-small-cell lung cancer. All of the patients received infusions of pembrolizumab every two to three weeks. The researchers also analyzed their tumor samples to measure levels of PD-L1.

Of the whole study group, 19 percent responded to the treatment, meaning their tumors shrank by at least 30 percent, lead author Edward Garon, M.D., an associate professor of medicine at the University of California, Los Angeles, told HealthDay.

But among patients with PD-L1 activity in at least half their tumor cells, 45 percent responded to the drug. After about a year of follow-up, most of the study patients with high PD-L1 levels were still alive, Garon said.

The most common side effects were fatigue, skin rash, and appetite loss. But about 10 percent of patients had more severe side effects, Garon said. Nine developed serious cases of pneumonitis of grade 3 or greater, including one patient who died.

RELATED: Pseudomonas Preparation May Improve Response Rate in Lung Cancer

"In conclusion, we have shown the efficacy and safety of pembrolizumab for previously treated and previously untreated patients with non-small-cell lung cancer," the authors write.

"Prospective testing of PD-L1 expression is feasible and retrospectively identified patients with an enhanced likelihood of having a clinical benefit from treatment with pembrolizumab."

The research was supported by Merck Sharp & Dohme, a subsidiary of Merck.

Reference

  1. Garon, Edward B., MD, et al. "Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer." The New England Journal of Medicine. DOI: 10.1056/NEJMoa1501824. [epub ahead of print]. April 19, 2015.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters